Background {#Sec1}
==========

Out-of-hospital cardiac arrest (OHCA) remains a challenge for prehospital rescue. With an incidence between 5 and 15 per 10,000 and a survival rate of only 6 to 11% \[[@CR1]--[@CR6]\], there is still room for improvement in care to reduce the morbidity and mortality of these patients. The quality of cardiopulmonary resuscitation (CPR) is at the heart of the last three 5-year recommendations \[[@CR7]--[@CR9]\]. The latest recommendations emphasize the importance of professionals applying the highest possible quality of CPR and chest compressions (CC) \[[@CR9]\].

The ratio of the time during which the CC are performed (low-flow) to the total time of resuscitation is referred to as the chest compression fraction (CCF). During CPR, minimizing CC interruptions, and therefore increasing the CCF, is essential, as this is an independent factor of cardiac arrest (CA) survival \[[@CR10], [@CR11]\]. CC interruptions are deleterious in at least three ways. First, they are a source of direct stoppage of cerebral and coronary perfusions, potentially altering the neurological prognosis and the probability of return of spontaneous circulation (ROSC) \[[@CR12]\]. Second, the quality of the cardiac output generated by CC drops when resuming after an interruption of more than 30 s, the cutoff below which several CC can restore the best cardiac output possible \[[@CR12], [@CR13]\]. Third, CC interruptions automatically decrease the CC rate per minute, and difficulty in reaching the upper target of the guidelines' CC rate has been linked to a significantly higher ratio of ROSC \[[@CR14]\]. Reducing these interruptions and improving CC is therefore a major goal of improving CPR. The recommendations state that the CCF must be greater than 60%, and some experts estimate that a CCF of 80% is possible \[[@CR15], [@CR16]\].

The outcome of out-of-hospital cardiac arrest (OHCA) is significantly, positively, and independently correlated with the suitability for different CCF targets, CC frequency, CC depth, and brief predefibrillation pause (\< 10 s) \[[@CR17], [@CR18]\]. Mechanical CC devices have not proven their superiority over manual CC \[[@CR19]\], and manual CC remains the gold standard. There is evidence that CC guidance improves adequacy to recommendations and allows closer alignment with the CC frequency, depth, and release objectives \[[@CR20]\]. We have demonstrated in simulation that the guidance of the CC delays the deterioration of the overall quality of the CC and its components (frequency, depth, and release) related to fatigue during an extended CC beyond the 2-min CC relay currently recommended \[[@CR21]\].

Strategies to better match the recommendations regarding the quality of the CC associated with an improvement in CC should add or even enhance their beneficial effects for the management of CA. Achieving high-quality CPR requires the measurement of the CPR quality (CC and CCF) \[[@CR22], [@CR23]\].

This idea of a strategy of support enhanced by the "bundle" of concepts is developing in the literature. Thus, Cheskes et al. \[[@CR24]\] describe a "high-quality CPR" such as the combination of a CCF greater than 70% and reaching the objectives in the recommendations for frequency and depth of CC.

The use of tools guiding CC quality still needs to be specified. Indeed, studies on their use in real-life situations are criticized for their methodological qualities and their sample sizes \[[@CR25]\]. The use of a real-time guidance tool is proposed as an option in the latest recommendations without being mandatory due to a lack of current evidence \[[@CR9]\]. Its use or nonuse does not imply any obvious loss of success for the patients. Evidence of its usefulness therefore remains to be sought.

For this reason, we want to perform an original, randomized, multicenter study to provide some answers to questions about the possibility of improving CCF by lengthening the time between two CC relays and the effect of guidance on the quality of the CC.

The design of the study will also allow us to investigate a possible combined effect of CC guidance and CC relay timing. The duration of a 2-min CC cycle between the two currently recommended relays does not have a solid evidence-based rationale and corresponds to a duration for which the CC effort can a priori be maintained while retaining efficiency \[[@CR9], [@CR26]\]. Objective measures have shown that the quality of the CC can be sustained beyond 2 min. Increasing the duration of a CC cycle could reduce the number of CC interruptions and thus improve the CCF.

We therefore formulate two hypotheses that we will test simultaneously using a 2 × 2 factorial design in a multicenter, randomized trial. The first assumption is that a 4-min relay rhythm improves the CCF (reducing the no-flow time) compared to the currently recommended 2-min relay rate. The second hypothesis is that a guiding tool improves the quality of CC.

The CPRmeter^®^ (guidance tool used in this study) will record data on the CC and their quality (depth, frequency, release, CPRmeter^®^ use time, no-flow time, and low-no-flow time) and will provide real-time feedback on CC for the guided group (the other group---blind---will have the screen masked by a screen cap).

Over a period of 2 years, this study will include 500 adult patients presenting with a nontraumatic OHCA for which advanced CPR is undertaken. We hope to improve the knowledge on the optimal rhythm of the CC relay and to validate "in vivo" the value of the guidance attained on manikins. This study should clarify the recommendations with a high level of evidence in this area and thus contribute to improving the prognosis of victims of OHCA.

Trial objectives {#Sec2}
----------------

The two main objectives of the 2 × 2 factorial plan are as follows: Objective 1: To determine whether the CCF gained from the CC relay rhythm of 4 min or 2 min is superiorObjective 2: To determine whether the quality of the CC, as measured by correct compression score (CCS), is superior with guidance or with blinding

Methods {#Sec3}
=======

Study design and settings {#Sec4}
-------------------------

We propose a randomized, multicenter, open-label study using a 2 × 2 factorial design (Protocol CILICA-HS version 4, June 26, 2019) comparing (i) the rhythm of CC relays every 4 min versus every 2 min on the CCF and (ii) the use of real-time guidance of the CC via a guidance tool (CPRmeter^®^) versus no guidance on the quality of the CC (correct compression score). Emergency prehospital services (Service Mobile d'Urgences et de Réanimation) from 12 hospitals in France will participate. The design of the study is summarized in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Study design

The two main objectives of the factorial plan are as follows: To determine whether a CC relay rhythm of 4 min or 2 min is superior in terms of CCF. CCF corresponds to the fraction of CPR time during which there are CC (low-flow) performed by the out-of-hospital resuscitation team on the OHCA patient.To determine whether the quality of the CC, measured by CCS, is superior with guidance or without guidance (corresponding to good depth, frequency, and release).

The secondary objectives of this study are to determine whether the impact of the guidance on the quality of the CC and on CCF has an isolated or combined effect on the patient's outcome: ROSC; survival at day 0, day 1, and day 30 (or earlier intensive care exit); the level of brain injury marker neuron-specific enolase (NSE); and neurological outcome at day 30 (or earlier intensive care exit) (CPC score).

Selection of participants {#Sec5}
-------------------------

Potentially eligible subjects are those with an OHCA for whom an out-of-hospital resuscitation team from an investigative center is involved in the first attempt at resuscitation.

Inclusion criteria {#Sec6}
------------------

To be eligible, subjects must meet all defined inclusion criteria: AdultVictim of an OHCAEligible for inclusion procedure in immediate life emergencyAffiliated with the social security system

Noninclusion criteria {#Sec7}
---------------------

A "noninclusion criterion" refers to a criterion identified or known prior to randomization that prevents inclusion in the study. Subjects meeting any of the following noninclusion criteria will not be eligible to participate in the research: Not an adultMore than 6 months pregnant or breastfeedingAbsence of indication or contraindication for resuscitation: known incurable disease (advanced neurodegenerative diseases, advanced cancers, ...), palliative care in progress, a do-not-resuscitate order from the patient or a decision by the medical team not to resuscitateTraumatic cardiac arrestImpossibility or contraindication to the use of the CC guidance system

Exclusion criteria {#Sec8}
------------------

An "exclusion criterion" refers to a secondary finding of a criterion that could not be identified prior to inclusion in the study and that justifies the patient's exclusion from the study. Subjects meeting any of the following exclusion criteria will not be eligible to participate in the research: Medical resuscitation started before inclusion by a noninvestigative teamAn automatic CC device was set up before 5 min of CPR in the protocolThe CPRmeter^®^ adhesive could not be fixed on the patient's torso (large breasts, heavy hair, anatomical abnormality, etc.)Obvious impairment of the CC quality linked to the use of the CPRmeter^®^Discontinuation of CPR before 4 min (excluding ROSC) due to the secondary discovery of the absence of an inclusion criterion or the presence of a noninclusion criterionDiscovery after the arrival of the medical team of an unidentified noninclusion criterion at the time of randomization

Blinding {#Sec9}
--------

The participants will be in cardiac arrest at the time of their enrollment and at the time of performance of the intervention; they will not be aware of the arm of randomization to which they are initially assigned and will be informed as soon as their clinical status allows it.

The study does not involve a blind setting for the healthcare providers, but outcome assessors and data analysts will be blinded to allocation groups C or D. Data are automatically blinded by the system when they are entered in the online electronic case report form (eCRF). The blinding is not completely possible for groups A and B because the length of the CPR relay differs between the 2 groups and is visible on the data regardless of the allocation masking.

Randomization, allocation {#Sec10}
-------------------------

The block randomization, stratified by trial centers, is performed using a randomization list from a centralized secure online server (internet) 24/7. A backup solution with sealed opaque envelopes will be available in each vehicle participating in the study for situations that do not allow access to the secure randomization server (off-grid area, connection difficulty). There is a stratification of the draw at each center in a 1:1:1:1 distribution: (A + C) 2 min blind, (A + D) 2 min with guidance, (B + C) 4 min blind, and (B + D) 4 min with guidance (Fig. [1](#Fig1){ref-type="fig"}).

Device description {#Sec11}
------------------

The CPRmeter^®^ is a CC guidance device marketed by Laerdal (LAERDAL Medical France, Limonest, France) that provides real-time feedback on CC. The CPRmeter^®^ is placed under the hands of the CC provider on the patient's chest, where it is secured with a disposable adhesive (Fig. [2](#Fig2){ref-type="fig"}). The dimensions of the CPRmeter^®^ are 154 mm × 64 mm × 28 mm, and it weighs 227 g. Feedback data are provided to the user via a 26 mm × 26 mm color screen located above a 100 mm × 55 mm rubber surface for the positioning of the rescuer's hands. It provides visual feedback to guide the depth, release, and frequency of the CC (Fig. [3](#Fig3){ref-type="fig"}). The hand position is represented on the left part of the screen by a white cursor going up and down on a scale according to the CC. Green targets at the top and bottom of the scale illuminate when they are reached by the cursor. In the case of insufficient depth or release CC, yellow arrows appear to indicate the CC modification needed. The CC frequency is shown on the right side of the screen by a needle on a speedometer with a green target area in the middle that illuminates when reached by the needle. The target values are defined by the manufacturer (Laerdal^®^) according to the 2015 recommendations, in effect when the device was designed \[[@CR9]\]. The indications provided by the CPRmeter^®^ are visual only and not audio. All data are automatically recorded in real time on the internal memory of the device. Fig. 2Position and use of CPRmeter^®^ during external chest compressionFig. 3CPRmeter^®^ screen display and feedback provided during external chest compression

The implementation of the device will be done in collaboration with the Laerdal^®^ Company, which will provide theoretical and practical initial training of investigative teams on the use of CPRmeter^®^ and data recovery before the start of the trial. The presentation and training for the use of the device will be of sufficient duration, and the mastery of the device will be ensured.

Trial interventions {#Sec12}
-------------------

CA, matching the eligible criteria, managed by an out-of-hospital resuscitation team can be included according to a procedure of immediate vital emergency (article L1122-1-3 of the Code of Public Health) \[[@CR27]\]. The randomization is performed by the out-of-hospital resuscitation team's doctor during the transportation on the spot to know the randomization arm before the arrival at the place of the intervention. The patient is randomized using the online centralized 24/7 server or the backup sealed opaque "off-grid area" emergency randomization envelopes as described in the "[Randomization, allocation](#Sec10){ref-type="sec"}" section above.

For all groups, the CPRmeter^®^ CC guidance system was positioned on the patient's chest with a disposable adhesive. The CPRmeter^®^ is always on for all groups. (1) In the CC guidance situation by the CPRmeter^®^ (group D), rescuers have onscreen real-time visual feedback on the quality of the CC performed and indications of corrections to improve the quality, if necessary. (2) In cases of nonguidance of the CC by the CPRmeter^®^ (blind), a specific screen cap is set up on the screen to hide the feedback in the unguided group (group C). The CPRmeter^®^ is always on to record the CC quality data.

The duration or rhythm of a relay is the time during which a rescuer performs a CC before being relayed by another rescuer. This time is 2 min in group A according to the guidelines in effect and 4 min in group B, which is the experimental group.

The CPR of OHCA is therefore normally undertaken according to the guidelines in effect by the out-of-hospital resuscitation team, except for the relay rhythm in group B, which is 4 min. Due to the 2 × 2 factorial design, four situations are possible (Fig. [1](#Fig1){ref-type="fig"}): CC unguided + relay between 2 rescuers switching at 2 min (C + A)CC unguided + relay between 2 rescuers switching at 4 min (C + B)CC guided + relay between 2 rescuers switching at 2 min (D + A)CC guided + relay between 2 rescuers switching at 4 min (D + B)

Apart from the guidance or blinding of the CC and the duration of the CC relays, the resuscitation is similar to the usual practice of the out-of-hospital resuscitation team and complies with the guidelines in effect \[[@CR9]\]. In case of use in relay of the CC of an automated CC device, the patient remains included in the study, the CPRmeter^®^ data (main judgment criteria) are retained, but no more data (secondary criteria) are collected after the implementation of the automated CC device (no blood sampling or CPC score).

Low-flow time is the time during which a CC is performed, generating a minimum cardiac output toward the organs. The no-flow time is the time during which no CC is performed. There is therefore no organ perfusion generated. The no-flow and low-flow times are complementary, and their sum is the patient's management time. The CCF is the percentage of time during which the patient receives CC over the entire time of rescue (CCF = low-flow time/total time). CC quality data (depth, release, and frequency) as well as time with CC (low-flow) and no CC (no-flow) are automatically collected by the CPRmeter^®^.

The data are collected online via the RéAC registry interface (<http://www.registreac.org/>), for which a direct data download functionality of the CPRmeter^®^ has been developed in collaboration with Laerdal. The data recorded by the CPRmeter® will therefore be retrieved from the memory after the end of the support upon return to the out-of-hospital resuscitation team's base and will be transmitted securely---at the same time as those relating to the patient's care---by Bluetooth connecting the CPRmeter^®^ to the RAC data collection server.

The patient, the family members, or the person of trust will be informed as soon as possible, and their consent ([supplementary file](#MOESM1){ref-type="media"}) will be sought for the possible continuation of this research (according to article L1122-1-3) \[[@CR27]\].

### Follow-up under study {#Sec13}

An NSE measurement will be performed upon the patient's admission and on day 3 in accordance with the guidelines for the management of postanoxic coma states \[[@CR28]\]. Blood samples will be collected into dry blood test tubes at the same time at admission and on day 3 to be sent to the University Hospital of Caen, Center for Biological Resources (CRB InnovaBIO, qualified NFS-96-900). The purpose is to perform a centralized NSE measurement (due to the large variability in the results from one laboratory to another). Samples will be sent within 30 min after sampling to the patient's hospital center for biological resources (CRB), where they will be centrifuged and frozen at − 80 °C (within a time period of less than 2 h after sampling) and stored in a deep-freeze (− 80 °C) pending repatriation (every 2 months) of all the cryotubes (dry-ice shipping with temperature control) to the Center for Biological Resources (CRB InnovaBIO) of the University Hospital of Caen for analysis. The cryotubes (aliquots needed for dosing) will then be yielded and transferred from the CRB InnovaBIO, in dry ice, to the biochemistry department of the University Hospital of Caen for centralized measurement.

The survival and the CPC score (Table [1](#Tab1){ref-type="table"}) \[[@CR29]\] are collected on day 1 by the investigator in coordination with the patient's unit and are sent to the data collection server. Table 1Cerebral performance category (CPC) scoreScoreDescription1Good cerebral performance2Moderate cerebral disability3Severe cerebral disability4Coma or vegetative state5Death

### End of study {#Sec14}

At day 30 or upon discharge from the intensive care unit, if earlier, or upon the death of the patient, the investigating physician, in coordination with the last unit where the patient was, will collect the following data: survival, number of days of survival in case of death between day 1 and day 30 (or at the exit of resuscitation if earlier), and CPC score \[[@CR29]\].

No long-term follow-up is planned.

### Concomitant care and interventions {#Sec15}

No concomitant medications, care, or intervention are prohibited as long as they do not interfere with the rhythm of CC relay or feedback device (CPRmeter^®^) use. The use of an automatic CC device set up before 5 min of CPR in the protocol is an exclusion criterion. If it is set up after 5 min, the collection of the CC data is restricted to those recorded before.

Outcomes {#Sec16}
--------

### Primary outcomes {#Sec17}

Since this is a factorial-design study, there are two primary outcomes: The chest compression fraction (CCF) (as a percentage) will be used for the comparison between a 2-min versus 4-min (A vs B) relay of CC. CCF is defined according to Saldanha et al. \[[@CR30]\] as a measure of quality of CPR (domain), corresponding to the relative amount of time during which the CC are performed during CPR (specific measurement), formally computed as the ratio of CPR time during which CCs are performed (low-flow) divided by the CPR time performed on the patient by the out-of-hospital resuscitation team. No-flow (no CC performed), low-flow, and CPR times (in seconds) are automatically recorded in real time by the CPRmeter® (metric). The mean CCF will be aggregated for 2 min versus 4 min (A vs B groups) (method of aggregation). The time point of interest for this endpoint is over the duration of CPR (time point).The correct compression score (CCS) (as a percentage) will be used for the comparison between real-time feedback guidance by CPRmeter^®^ versus no real-time feedback guidance by CPRmeter^®^ (C vs D). CCF is defined according to Saldanha et al. \[[@CR30]\] as a measure of quality of CPR (domain), corresponding to the percentage of CC for which the depth is correct (50 to 60 mm), the frequency is correct (100 to 120/min), and the relaxation is correct (\< 2500 g) (specific measurement). The depth (in millimeters), the frequency (number of compressions per minute), and the release (residual strength in grams) of the CC are automatically recorded in real time by the CPRmeter^®^ (metric). The mean CCS will be aggregated for real-time feedback guidance by CPRmeter^®^ versus no real-time feedback guidance by CPRmeter^®^ (C vs D groups) (method of aggregation). The time point of interest for this endpoint is over the duration of CPR (time point).

### Secondary outcomes {#Sec18}

The secondary outcomes are as follows: The depth of each CC (in millimeters), recorded continuously by the guidance system (average and percentage correct)The frequency of CC (in number of compressions per minute), recorded continuously by the guidance system (average and percentage correct)The release of the CC, corresponding to the residual force (in grams), recorded continuously by the guidance system (average and percentage correct)The subjective fatigability, assessed by the rescuers who performed CC using the Borg scale (average of the Borg rescuer scale values) \[[@CR31]\]Time and length of care (in minutes and seconds) based on the following events: CA time, CC start time, the out-of-hospital resuscitation team's resuscitation start time, and resuscitation end time (ROSC or death of the patient)The length (in minutes and seconds) of no-flow and low-flow: no-flow and low-flow times prior to the arrival of the out-of-hospital resuscitation team (declarative) and no-flow and low-flow times during resuscitation by the out-of-hospital resuscitation team (measured by the CC guidance device)The rate of return of spontaneous circulation (ROSC)The survival rate at hospital admissionThe value of NSE at admission and day 3 \[[@CR28]\]The survival rate on day 1 and day 30 (or resuscitation output if earlier)Cerebral performance category score (CPC) at day 30 or intensive care discharge \[[@CR29]\]

The study will be conducted within the framework of the French national network of the RéAC Cardiac Arrest Registry (<http://www.registreac.org/>).

Data collection {#Sec19}
---------------

Data will be collected using international Utstein-style guidelines on reports for OHCA and using the automatic data registration of the CPRmeter^®^ device. Data from the CPRmeter^®^ will be uploaded to the section of the French national network of the RéAC Cardiac Arrest Registry (<http://www.registreac.org/>) dedicated to the study. All other data will be collected by doctors in charge of the patient and entered into an eCRF of the dedicated section of the RéAC Cardiac Arrest Registry. Clinical research assistants (locally and in the promoting center) will help and monitor the data collection and the eCRF. The data input is checked by computer.

Apart from the CC quality data report by the CPRmeter^®^, data collection will be performed as follows:

### At day 0 {#Sec20}

Demographic characteristics: identity, social security number, intervention, street address, age (year), sex (male/female), weight (estimated, in kilograms), height (estimated, in meters)Patient history: medical history (cardiovascular, respiratory, diabetes, end of life, others)History of the disease: presumed etiology of CA (cardiac, neurological, respiratory, asphyxiation, poisoning, drowning, unknown, others), durations of no-flow and low-flow periods before medical resuscitation (minutes), existence of witnesses, resuscitation maneuvers undertaken before the arrival of professional rescuers (CC, defibrillation, ventilation)History of the advanced CPR carried out by the out-of-hospital resuscitation team: Duration of low-flow, no-flow, and advanced resuscitation (minutes, obtained by CPRmeter^®^ recording)Quality of the CC and its components (frequency in CC per minute, depth in millimeters, and release in grams obtained by the CPRmeter^®^ recording)EtCO~2~ values (mmHg) 1 min (± 20 s) after intubation, the highest obtained during CC (before ROSC) and at the end of resuscitation (1 min ± 20 s after the ROSC or during the decision to end resuscitation) \[[@CR32], [@CR33]\]External electrical shocks (number, intensity in joules)Initial rhythm upon the out-of-hospital resuscitation team arrival (asystole, ventricular fibrillation, ventricular tachycardia without pulse, electromechanical dissociation)Numbers and total doses of vasopressor amines and antiarrhythmic administration (milligrams)ROSC or death

Survival at hospital admission

### At hospital discharge or at day 30 {#Sec21}

Values of the NSE performed upon the patient's admission and on day 3 (in micrograms per liter) \[[@CR28]\]Survival on day 1 and day 30 (or at the intensive care unit (ICU) discharge if earlier)Length of stay in the ICU (days)Neurological state assessment by the CPC and any sequelae on day 1 and at ICU discharge or on day 30 \[[@CR29]\]

Data management {#Sec22}
---------------

Trained research staff (clinical research assistants) at each center will collect data using an online national secure database dedicated to cardiac arrest data collection (RéAC; <http://www.registreac.org/>). The two different eCRF pages for prehospital and intensive care will be completed separately. Data on CC quality from the CPRmeter^®^ will be uploaded with the clinical data from the prehospital period. Deidentified completed data will be sent to the principal investigator at Caen University Hospital. Furthermore, data will be monitored by a data manager. The clinical research manager and two clinical research assistants from the steering committee will be available to help and monitor the data collection and management.

Data monitoring committee {#Sec23}
-------------------------

The data monitoring committee from the national cardiac arrest registry RéAC will ensure the first level of independent data monitoring. A specific-to-the-study data monitoring committee composed of a senior data manager and an assistant data manager (independent from the primary sponsor and the steering committee) will regularly control the maintenance of the informatic system, check the quality of the data entered, and ensure the proper functioning of the automatic data entry control system.

Safety and potential adverse events {#Sec24}
-----------------------------------

The study implies few changes from OHCA guidelines as real-time feedback is not currently strongly recommended but a possibility, and the time for CPR relay is based on little concrete data \[[@CR15]\]. However, feedback tool use has been reported to be safe \[[@CR20], [@CR34]\]. In the context of an OHCA, no significant adverse event related to the study is expected. Adverse events can be reported through eCRF, email, and phone calls to the promoter. Serious adverse events will be investigated, and reports will be provided directly to the safety monitoring committee. If they occur, adverse events will be reported in the publication.

Safety monitoring {#Sec25}
-----------------

A trio of independent experts not involved in the study (safety monitoring committee) will meet when 250 patients have been included to review the monitored data on ROSC and survival on day 0, day 1, and day 30 according to the randomized group. The investigator can request an extra meeting at any time in case of new data in the literature or if an event occurs in the study requiring the safety monitoring committee's advice.

Steering committee {#Sec26}
------------------

A steering committee composed of the principal investigator, a statistician, a clinical research manager, and two clinical research assistants will be in charge of the presentation, the implementation and follow-up of the study at the different participating centers, and the overall management of the study (coordination of the data management team and safety committee).

Auditing {#Sec27}
--------

Research assistants from the steering committee will conduct at least one onsite monitoring visit per year over the course of the study at 100% of the recruiting sites (with repeat visits to sites where performance is a concern). The primary objectives during the onsite visits are to educate, support, and solve problems. At the start of the trial, the monitors will conduct a tutorial on the procedure to extract data from the CPRmeter^®^ and on the online data entry system. The investigators will practice so that the monitors can confirm that the investigators are proficient in all aspects of data extraction and entry.

Schedule of data collection {#Sec28}
---------------------------

Intervention assignment will be performed before starting the trial. If patients survive their CA, they will be followed up for 1 month after enrollment. The schedule of data collection is summarized in Table [2](#Tab2){ref-type="table"}. Table 2Schedule of data collection

Trial registration {#Sec29}
------------------

The trial was registered on 28 January 2019 at <http://www.clinicaltrials.gov> under number NCT03817892 (<https://clinicaltrials.gov/ct2/show/NCT03817892?term=buleon&draw=2&rank=1>).

Statistical analyses {#Sec30}
--------------------

The main analysis population will be defined as all randomized patients for whom CPR has been engaged, according to a modified intent-to-treat principle. Randomized patients who do not fulfill the inclusion criteria, die, or have a ROSC at prehospital team arrival will be excluded from the main modified intent-to-treat principle analysis. We plan to conduct a pure intent-to-treat analysis in which these excluded patients and patients with missing data will have their outcome imputed by multiple imputation process. This analysis will test the effect of these exclusions on trial outcomes. The statistical analysis plan will follow the recommendations of the tests with a factorial plan described in the CONSORT statement \[[@CR35]\], namely, (i) the verification of the absence of interaction between the 2 interventions tested (here on different criteria of judgment) and (ii) a separate analysis by type of multivariate intervention that will systematically include the effect of the untested intervention. Regarding the main criterion of judgment, the average percentage of CCF for comparison of A versus B and the average percentage of CCS for comparison C versus D, the two groups will be compared in terms of superiority of the 4-min group (B) and the guidance group (D) by a multivariate generalized linear regression model including the randomization group as an explanatory variable as well as the other intervention received as a covariable of the model and possibly the interaction of the 2 interventions if it is significant (Student's test for independent series).

The other criterion (secondary outcomes) will be compared between the groups using the appropriate tests and in an exploratory manner. For example, the qualitative variables will be compared between the groups with the *χ*^2^ test, the quantitative variables by Student's *t* test, and the survival by the log-rank test.

All confidence intervals of the parameters to be estimated will be established at 5% risk (95% confidence interval). No interim analysis will be performed for primary outcomes (CCF and CCS). The significance level is set at 0.05. The analysis will be performed in SAS software v9.4 (SAS Institute NC, Cary).

Determination of sample size {#Sec31}
----------------------------

We estimated the calculation of the number of subjects required in this trial using a factorial design for the comparison of 2 min versus 4 min (A vs B) on the average percentage of CCS.

With an average CCF of 70% \[[@CR36]\] in the control group (group A, 2 min) and a 5% improvement in the experimental group (group B, 4 min), a power of 90%, a two-tailed alpha risk of 5% bilateral, and a standard deviation of ± 17%, 243 subjects per group are required to compare the effect of 2 min versus 4 min (A vs B) on the average percentage of CCF.

Regarding the guiding hypothesis, with a difference of 15% in the CCS between the guided group (D) and the blinded group (C), a standard deviation of ± 36% (12), alpha 5%, and beta 10%, the number of subjects needed is lower (122 per group).

We plan to include 500 patients according to the sample size needed for hypothesis A vs B (243 per group), which is higher than that needed for hypothesis C vs D (122 per group).

Discussion {#Sec32}
==========

The study will contribute to the field of literature on the impact of real-time feedback on CC quality in practical conditions of OHCA resuscitation. No definitive position on the benefit of real-time feedback on CC quality has been assessed \[[@CR9], [@CR20]\]. This topic is complicated and has many possible confounding factors and biases. A definitive answer will probably come from a meta-analysis or a large-scale study. It seems to us that this study can be one of the small steps toward a conclusion.

The study will also provide insight into the feasibility of extending the switch time duration between two rescuers from the currently recommended 2 to 4 min. Beyond feasibility, it will provide clues on the effect of an extension of the switch time on the CC quality. With the two groups, guided and blinded to real-time feedback, it will also determine whether an extension of the switch time provides a CC quality as efficient as the current 2 min regardless of real-time feedback, only with real-time feedback or whether CC quality decays even with real-time feedback. Even if the extension of the switch time does not have a positive effect on CC quality, we will have concrete data on its effect on the chest compression fraction time. Since this has been highlighted as a determining element of the quality of resuscitation, it will provide an interesting perspective for future research and care in CA. As an anticipated limitation, we know that the sample size---designed to answer our questions---will probably be insufficient to provide significant data on mortality and morbidity. However, we believe this study may help provide a clearer view of some important aspects of the management of OHCA and may open new opportunities for further research.

Trial status {#Sec33}
------------

The trial is ongoing, and patient recruitment is active. The first patient was included on December 6, 2019. The recruitment is estimated to be completed by November 30, 2021 (protocol version 4 from June 26, 2019).

Supplementary information
=========================

 {#Sec34}

###### 

**Additional file 1.** Patient informed consent to continue a study.

###### 

**Additional file 2.** World Health Organization Trial Registration.

CA

:   Cardiac arrest

CC

:   Chest compression

CCF

:   Chest compression fraction

CCS

:   Correct compression score
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:   Cerebral performance category

CPR

:   Cardiopulmonary resuscitation

eCRF

:   Electronic case report form
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:   End-tidal carbon dioxide (CO~2~)

ICU

:   Intensive care unit
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:   Neuron-specific enolase
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:   Out-of-hospital cardiac arrest

ROSC

:   Return of spontaneous circulation
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Ancillary and posttrial care {#FPar1}
============================

Patients who are enrolled in the study are covered by indemnity for negligent harm through the standard national Indemnity Fund. The University Hospital of Caen has insurance to cover for nonnegligent harm associated with the protocol. This will include cover for additional health care, compensation, or damage, whether awarded voluntarily by the sponsor or by claims pursued through the courts. Incidences judged to arise from negligence (including those due to major protocol violations) will not be covered by study insurance policies. The liability of the manufacturer of CPRmeter® is strictly limited to those claims arising from faulty manufacturing of the commercial product and not to any aspects of the conduct of the study.

Trial results {#FPar2}
=============

Once the study is completed, the results will be communicated via publication in a journal and presentation at conferences and will be reported on clinicaltrials.gov. The scientific integrity of the project requires that the data from all sites be analyzed study wide and reported as such. Thus, an individual center is not expected to report the data collected from its center alone. All presentations and publications are expected to protect the integrity of the major objectives of the study. Each paper or abstract must be submitted to the steering committee for approval. Every attempt will be made to reduce to an absolute minimum the interval between the completion of data collection and the release of the study results. We expect to take approximately 3 to 4 months to compile the final results paper for an appropriate journal. The study results will be released to the participating physicians, referring physicians, and the medical community.

Authorship {#FPar3}
==========

Substantive contributions to the design, conduct, interpretation, and reporting of the study will be recognized through the granting of authorship on the final study report.

No professional writer has been employed for the study protocol, nor is it planned to hire one for the final study report.

BC and PJJ designed the trial, wrote the protocol, reviewed the protocol, and wrote the article. RE and GPY reviewed the design of the trial and reviewed the protocol and the article. HL, CE, JB, BC, HK, AF, BX, MME, AA, and VC reviewed the protocol and the article. The authors read and approved the final manuscript.
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The University Hospital of Caen (Direction de la Recherche Clinique et de l'Innovation, CHU de Caen Normandie, Avenue Cote de Nacre 14000 Caen, France) is the sponsor of the study. Tel: + 33(0)231065781; email: drci-sec\@chu-caen.fr

Only the steering committee has access to the full trial dataset to ensure the overall results. Site investigators may access their site or the full dataset if a formal request describing their plans is approved by the steering committee.

The trial protocol is available online on clinicaltrial.gov. Three years after the end of the collection of the data, once all publications related to the study will be done, the full dataset will be accessible with the steering committee's approval upon formal request describing the purpose.

The South-West and Over-Sea 4 Ethics Committee (IRB No.: IORG0009855, Chairperson Claire Bahans) approved the study on November 9, 2018, under the registration number CPP18-071a/2018-2000-55, amended on August 29, 2019, under reference AM2019-171/02/CPP18-071. Because of the cardiac arrest status of the patients in the trial and the need to proceed with the intervention in a timely manner, according to the French Public Health law on clinical research in emergency conditions (art. L1122-1-2), prior informed consent was waived. The patient's consent ([supplemental file](#MOESM1){ref-type="media"}) will be asked and written when and if possible in the ICU by the medical staff in charge of the patient. If not possible (death of the patient), the data gathered will be used. Any change in the study design will be subject to a protocol amendment reviewed and submitted to the ethics committee for approval and then updated in the Clinical Trial registration.

Additional biological samples will be obtained to be stored for use in future studies of the pathobiology of CA for patients who will be hospitalized in the ICU. Material consent will be obtained to specifically address the collection of these blood samples. Signed consent must be obtained from every patient in the ancillary study when and if possible in the ICU by the medical staff in charge.
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